司库奇尤单抗在银屑病关节炎和强直性脊柱炎治疗中的作用。
The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.
作者信息
Garcia-Montoya Leticia, Marzo-Ortega Helena
机构信息
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
LIRMM, University of Leeds, Second floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.
出版信息
Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):169-180. doi: 10.1177/1759720X18787766. eCollection 2018 Sep.
Abstract
Psoriatic arthritis and ankylosing spondylitis are chronic inflammatory diseases that can cause significant disability. The commercialization of the first tumour necrosis factor (TNF) inhibitors led to a radical improvement of the quality of life of people affected by these conditions; however, response was not universal, highlighting the need for alternative therapeutic targets. Secukinumab is a monoclonal interleukin (IL)-17A inhibitor which has been proven efficacious for psoriatic arthritis and ankylosing spondylitis in recent clinical trials. Dactylitis, enthesitis, skin and nails are some of the domains in which the inhibition of IL-17 has shown significant improvements apart from the joints. Its safety profile and satisfactory medium- to long-term outcome data are some of the aspects suggesting its potential impact in treatment protocols in the short term.
摘要
银屑病关节炎和强直性脊柱炎是可导致严重残疾的慢性炎症性疾病。首批肿瘤坏死因子（TNF）抑制剂的商业化使这些疾病患者的生活质量得到了根本性改善；然而，并非所有患者都有反应，这凸显了寻找替代治疗靶点的必要性。司库奇尤单抗是一种单克隆白细胞介素（IL）-17A抑制剂，在最近的临床试验中已被证明对银屑病关节炎和强直性脊柱炎有效。除关节外，指（趾）炎、附着点炎、皮肤和指甲等部位的IL-17抑制也显示出显著改善。其安全性和令人满意的中长期疗效数据表明，它在短期内可能会对治疗方案产生影响。
相似文献
1
The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.司库奇尤单抗在银屑病关节炎和强直性脊柱炎治疗中的作用。
Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):169-180. doi: 10.1177/1759720X18787766. eCollection 2018 Sep.
2
Secukinumab for the treatment of psoriatic arthritis.司库奇尤单抗治疗银屑病关节炎。
Expert Rev Clin Immunol. 2016 Oct;12(10):1027-36. doi: 10.1080/1744666X.2016.1224658. Epub 2016 Aug 25.
3
Secukinumab: A Review in Psoriatic Arthritis.司库奇尤单抗：治疗银屑病关节炎的研究进展。
Drugs. 2016 Jul;76(11):1135-45. doi: 10.1007/s40265-016-0602-3.
4
Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: .司库奇尤单抗治疗附着点炎相关关节炎和银屑病关节炎的儿童和青少年患者： 。
Expert Rev Clin Immunol. 2024 May;20(5):435-440. doi: 10.1080/1744666X.2024.2303340. Epub 2024 Jan 10.
5
Secukinumab (AIN457) in the treatment of ankylosing spondylitis.司库奇尤单抗（AIN457）治疗强直性脊柱炎
Expert Opin Biol Ther. 2016;16(5):711-22. doi: 10.1517/14712598.2016.1167183.
6
Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.脊柱关节炎（包括银屑病关节炎）中抗肿瘤坏死因子治疗的最新进展。
Curr Opin Rheumatol. 2006 Jul;18(4):347-53. doi: 10.1097/01.bor.0000231901.19795.8a.
7
Secukinumab for rheumatology: development and its potential place in therapy.司库奇尤单抗用于风湿病学：研发及其在治疗中的潜在地位。
Drug Des Devel Ther. 2016 Jun 24;10:2069-80. doi: 10.2147/DDDT.S105263. eCollection 2016.
8
Secukinumab for ankylosing spondylitis and psoriatic arthritis.司库奇尤单抗用于强直性脊柱炎和银屑病关节炎。
Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592. doi: 10.2147/TCRM.S100091. eCollection 2016.
9
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.司库奇尤单抗：一种用于治疗银屑病的抗白细胞介素-17A生物制剂的综述。
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.
10
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.司库奇尤单抗治疗中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者五年的长期安全性：汇总临床试验和上市后监测数据的更新。
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
引用本文的文献
1
The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal Study.与第一种肿瘤坏死因子（TNF）抑制剂相比，司库奇尤单抗作为一线生物制剂治疗中轴型脊柱关节炎的保留率和安全性：一项真实世界的纵向研究。
Cureus. 2024 Sep 28;16(9):e70365. doi: 10.7759/cureus.70365. eCollection 2024 Sep.
2
T Helper 17-Like Regulatory T Cells in Equine Synovial Fluid Are Associated With Disease Severity of Naturally Occurring Posttraumatic Osteoarthritis.马关节滑液中 Th17 样调节性 T 细胞与自然发生的创伤后骨关节炎的疾病严重程度相关。
Am J Sports Med. 2023 Mar;51(4):1047-1058. doi: 10.1177/03635465231153588. Epub 2023 Feb 16.
3
Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.脊柱关节炎中的单核细胞和巨噬细胞：功能作用和当前治疗方法的影响。
Cells. 2022 Feb 2;11(3):515. doi: 10.3390/cells11030515.
4
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.真实世界中 608 例银屑病关节炎患者使用司库奇尤单抗的疗效和安全性：一项为期 24 个月的前瞻性、多中心研究。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001519.
5
T cell epitope mapping of secukinumab and ixekizumab in healthy donors.在健康供体中对司库奇尤单抗和依奇珠单抗的 T 细胞表位进行定位。
MAbs. 2020 Jan-Dec;12(1):1707418. doi: 10.1080/19420862.2019.1707418.
6
Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression.细胞外信号调节激酶：调节细胞生长、炎症、软骨细胞和骨细胞受体介导的基因表达的调节剂。
Int J Mol Sci. 2019 Aug 3;20(15):3792. doi: 10.3390/ijms20153792.
7
Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis.关于司库奇尤单抗用于银屑病关节炎和强直性脊柱炎的真实世界数据。
Ther Adv Musculoskelet Dis. 2019 Jun 19;11:1759720X19858510. doi: 10.1177/1759720X19858510. eCollection 2019.
8
Interleukin-17 in Antifungal Immunity.抗真菌免疫中的白细胞介素-17
Pathogens. 2019 Apr 22;8(2):54. doi: 10.3390/pathogens8020054.
本文引用的文献
1
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.司库奇尤单抗改善活动性银屑病关节炎症状和抑制影像学进展：来自随机、双盲、III 期 FUTURE 5 研究的主要结果。
Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.
2
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).司库奇尤单抗注射液治疗银屑病关节炎的疗效和安全性：一项随机、安慰剂对照试验（FUTURE 3）的结果。
Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.
3
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.司库奇尤单抗可维持银屑病关节炎体征和症状的改善：3期FUTURE 2研究的2年结果
Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.
4
A Review of the Use of Secukinumab for Psoriatic Arthritis.司库奇尤单抗用于银屑病关节炎的应用综述
Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28.
5
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.司库奇尤单抗抑制白细胞介素-17A在活动性强直性脊柱炎中的长期疗效：3期MEASURE 1试验扩展研究的3年疗效和安全性结果
Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50-55. Epub 2017 May 15.
6
International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.国际治疗推荐更新：来自GRAPPA 2016年会的报告。
J Rheumatol. 2017 May;44(5):684-685. doi: 10.3899/jrheum.170144.
7
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.司库奇尤单抗与活动性强直性脊柱炎患者体征和症状持续改善两年：一项III期研究结果
Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7.
8
Anti-IL17A in Axial Spondyloarthritis-Where Are We At?抗白细胞介素-17A在轴性脊柱关节炎中的应用现状如何？
Front Med (Lausanne). 2017 Jan 18;4:1. doi: 10.3389/fmed.2017.00001. eCollection 2017.
9
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.2016 年更新的 ASAS-EULAR 中轴型脊柱关节炎管理推荐。
Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13.
10
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.司库奇尤单抗治疗强直性脊柱炎的临床和放射学疗效：随机 III 期 MEASURE 1 研究的 2 年结果。
Ann Rheum Dis. 2017 Jun;76(6):1070-1077. doi: 10.1136/annrheumdis-2016-209730. Epub 2016 Dec 13.
Zotero 插件